ABSTRACT
‫عدوى‬ ‫عالج‬ ‫في‬ ‫ثرومايسين‬ ‫از‬ ‫تأثير‬ ( ‫الجلدية‬ ‫ليشمانيا‬
[10] Other drugs like azoles, rifampicin, metronidazole, paromomycin etc. are used for its treatment, but still SSG remains the first line of the treatment of CL despite its side effects and cost. [10] [11] [12] Many studies were conducted to optimize treatment of CL because resistant cases to the above mentioned treatments are going to grow up. [13, 14] Bacterial super-infection to lesions of CL is considered to be one of the complications of this disease which is incriminated to be the cause of the resistant cases to proven therapy. So that combating this super-infection is thought to be very helpful to reduce the possibility of resistance and better response to the treatment plan. [15] Macrolides especially azithromycin and clarithromycin had been studied to be effective against Leishmania species of old world, but these studies were not conducted on the lesions of human being. [16] [17] [18] Azithromycin due to its property of achieving high concentration in macrophages is promising in treatment of lesions of CL. [18.19] In Erbil governorate after the outbreak of CL we tried conduct this study to compare combination therapy of azithromycin and SSG intralesionally to SSG intra-lesionally alone as monotherapy.
PATIENTS AND METHODS
Prospective open labeled randomized controlled study conducted from September 2016 up to March 2017 in "Erbil Dermatology Teaching Center" in Erbil, Kurdistan, Iraq. Sixty three patients with cutaneous leishmaniasis were assigned to be included in this study. Patients were diagnosed clinically by two separate dermatologists and then confirmed parasitologically through detection of Donovan's bodies in the smears taken from patients' lesions. The study sample randomly divided into 2 groups; the patients randomized by block randomization method through possible balanced combinations with 2 patients to treatment group and the following 2 patients to control group. The first group A were 31 patients received intral-lesional (IL) sodium stibogluconate only, 0.5-1 ml per each lesion and the session repeated after 2 weeks, the second group B were 32 patients received intralesional sodium stibogluconate in the same dosage and frequency as in group A and oral azithromycin tablet 500mg three successive days per week for up to 2 months. Patients were controlled for the clinical improvement at two follow up points. 
RESULTS
Total 63 patients suffering from cutaneous leishmaniasis included in this study. Among them 49 were males and 14 were females. The age ranged between 7-64 years, the mean of 35 ± 10.4 years. There were no difference between mean ages of both group A and B (P > 0.05). (Table-1) . Majority of the lesions in this sample were nodular (71.5%). Ulceration was dominant characteristic of the lesions found in 59% of the lesions (Table-2 ). The duration of the lesions at the time of presentation was ranged between 3 and 9 weeks, mean of 3 ± 1.1 and 2.4 ± 1.8 weeks in patients of group A and B respectively. The difference between both group number of lesions and their durations was not found (P > 0.05). (Table-1 ). Commonest site of lesions were foot, forearms, hands, face and legs, 23%, 20%, 17% and 15% respectively. (Figure-2) . During the course of therapy no significant side effects of drugs had been observed apart from pain during intra-lesional injections in all patients, gastric upset in 3 patients and dizziness in 1 patient in the patients group receiving azithromycin orally in combination to IL sodium stibogluconate, while in patients receiving only IL sodium stibogluconate no such adverse effects seen apart from pain during intra-lesional injections.
DISCUSSION
Cutaneous leishmaniasis it is the parasitic infection that have different treatment options but no one was found to have satisfactory for both clinician and patient, in which resistance to treatment is the main problem that face therapy introduction. [20, 21] Sodium stibogluconate still is the treatment number one in management of CL in Iraq but emergence of difficult cases make to think about alternative ways of treatment. [20] In this study we tried to augment the effect of sodium stibogluconate by its combination with azithromycin orally. We observed that earlier resolution of the condition could be found in a very good proportion of the patients, at 6 th week of therapy when IL sodium stibogluconate combined with oral azithromycin 71.8% of patients while in cases of monotherapy with IL sodium stibogluconate was only in 41.9% of the patients (P < 0.001). Azithromycin has antiprotozoal and antileishmanial effect, [16, 17] Eglal and coauthors tried oral azithromycin in combination with multifosine for the treatment of Leishmania major infection in mice, they proved the effectiveness of this drug. [18] Secondary bacterial infection of CL lesions in some case could complicate course of the disease. [18.21] So that the synergistic effect of both azithromycin and sodium stibogluconate could be due to the antibacterial effect of azithromycin which can eliminate secondary bacterial infection of the lesions. In our study there were some cases that did not healed after 8 weeks therapy in patients receiving IL SSG (poor response 9.7% and good response 3.2%). This proportion could be due to strains that not respond to this treatment, as recently in some countries identification of species carried because drug and treatment plan is species directed. [22] We can conclude that further studies to be conducted to see the effect of these combination therapy on different species of CL in Iraq to identify the species which is sensitive to the suggest treatment. These need to provide identification of Leishmania species in all case of CL before the introduction of therapy which will provide more cost and time effective therapy; also it will reduce probability of nonresponding cases. According to the results of this study we conclude that oral azithromycin in combination with IL sodium stibogluconate can achieve earlier healing of the lesion and less possibility of resistant cases.
